Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.54 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enriched outside the brain (myonuclei) | 0.10 |
| chemistry Open Targets | compounds already reach it: riluzole, tocainide, phenytoin +74 | 1.00 |
| trials ClinicalTrials.gov | 1 Parkinson's trial, 0 stopped | 1.00 |
| literature PubMed | 2 Parkinson's papers of 473 | 0.85 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 11465
Earlier readings: 2026-10-26 0.45; 2026-10-25 0.45; 2026-10-24 0.45; 2026-10-23 0.45.
Sealed predictions
- SCN4A in dopamine neurons, braak-0.27 (p 0.476) → -0.22 (p 0.569)receipt 0161
Swarm cases
receipt 0161: SCN4A in dopamine neurons, braak
- power
- full sample -0.37 (p 0.130, n 18), 95% CI -0.71 to +0.12. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.40 (p 0.103, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.55 (p 0.019, n 18). not the mix.
- skeptic
- leave-one-out range -0.53 to -0.29, sign flips 0; without severely affected donors -0.37 (p 0.130, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SCN4A in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts